Valneva SE (“Valneva” or “the Company”), a specialty vaccine company, and Serum Institute of India (SII), a Cyrus Poonawalla Group company today announced that they have mutually agreed to discontinue their license agreement for Valneva’s single-shot chikungunya vaccine.
Valneva´s strategic intent in regaining full rights is to assume direct control over its supply chain and commercialization for endemic high-risk countries, thereby accelerating access for regions most affected by the disease.
https://finance.yahoo.com/news/valneva-serum-institute-india-announce-164500774.html
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.